Editas Medicine (EDIT) Stock Price, Quote, News & History | Benzinga

Editas Medicine Inc (EDIT) Stock Price, Quote, News & History

EDITNASDAQ

Trade with Public

Trade with Public

$3.16

-0.14-4.24%

At close: Aug 28, 5:00 PM EST

$3.14

-0.0193-0.61%

After Hours: Aug 28, 7:52 PM EST

OverviewNews Earnings Forecast Events Price Targets Financials Sentiment Ownership Compare Options Stock Report

Key Statistics

Open

$3.25

Close

$3.16

Volume / Avg.

3.27M / 2.72M

Day Range

$3.15 - $3.41

52 Wk Range

1.66 - 4.54

Market Cap

$482.35M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

16.1%

Days to Cover

14.59

Recent Editas Medicine, Inc. News

Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday

Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.

Avi Kapoor

Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday

Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in today's session.

Avi Kapoor

Abercrombie & Fitch Upbeat Q1 Earnings, Joins Digital Turbine, Dycom Industries And Other Big Stocks Moving Higher On Wednesday

Dow Jones up 300 points with gains from Abercrombie & Fitch, Digital Turbine, Dycom Industries, Qfin Holdings, Editas Medicine, and others.

Avi Kapoor

Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles

Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.

Akanksha Bakshi

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Julia Khandoshko

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-119.86M

Investing Cash Flow (TTM)

9.90M

Financing Cash Flow (TTM)

152.03M

Free Cash Flow (TTM)

-120.55M

Capital Expenditure (TTM)

-691.00K

Net Change in Cash (TTM)

42.07M

Analyst Trends and Forecast

2

Mar

1

May

1

Aug

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

2.9

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$287.64M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

7.10

PB Ratio (TTM)

4.81

Earnings Yield % (TTM)

-20.00%

Earnings Yield % (FWD)

-24.24%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

$0.69

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$181.82M

Debt to Equity

0.15

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$3.25

Close

$3.16

Volume / Avg.

3.27M / 2.72M

Day Range

$3.15 - $3.41

52 Wk Range

1.66 - 4.54

Market Cap

$482.35M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

55

Short Interest

16.1%

Days to Cover

14.59

About

Sector

Health Care

Industry

Biotechnology

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform base...

Show More

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Editas Medicine (EDIT) stock?

A

You can purchase shares of Editas Medicine (NASDAQ:EDIT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Editas Medicine (EDIT) competitors?

A

Other companies in Editas Medicine’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Q

What is the forecast, or price target, for Editas Medicine (EDIT) stock?

A

Editas Medicine has a consensus price target of $7.18.

Q

What is the current price for Editas Medicine (EDIT)?

A

The stock price for Editas Medicine (NASDAQ: EDIT) is $3.1407 last updated August 28, 2026 at 7:52 PM EDT.

Q

Does Editas Medicine (EDIT) pay a dividend?

A

There are no upcoming dividends for Editas Medicine.

Q

When is Editas Medicine (NASDAQ:EDIT) reporting earnings?

A

Editas Medicine does not have any upcoming earnings scheduled.

Q

Is Editas Medicine (EDIT) going to split?

A

There is no upcoming split for Editas Medicine.

Q

What sector and industry does Editas Medicine (EDIT) operate in?

A

Editas Medicine is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.